Eileen Goodwin

A family networker

A family networker

When she moved to North Taieri more than a decade ago, Lyn Robins had time on her hands.

Peters has harsh words for National

Peters has harsh words for National

The man who could be kingmaker at this year's general election says he is closer to Labour on economics, but disagrees with the party on social reform.

Stockpiling Tamiflu 'waste of money'

Stockpiling Tamiflu 'waste of money'

Millions of dollars spent hoarding Tamiflu are probably a waste of money that could fund other health services, University of Otago biostatistician Prof Peter Herbison says.

More effort urged on disarmament

More effort urged on disarmament

Senior United Nations officials have always assumed they are spied on, and it does not affect their work, a top UN representative says.

Suppressed Tamiflu research telling

Suppressed Tamiflu research telling

New research showing antiviral drug Tamiflu shortens the symptoms of flu by just 12 hours is raising questions about the billions of dollars spent by countries to stockpile it.

Ministry changes approach on helplines

The Ministry of Health has had a change of heart about the process it will follow to combine health helpline services, saying it wants to work with potential providers in a more collaborative way.

Neurosurgery in 'good shape'

Neurosurgery in 'good shape'

Southern and Canterbury district health boards now have joint responsibility for the neurosurgery service that caused serious tension when they could not agree on how it would be provided.

Flu peaks change with the climate

Flu peaks change with the climate

Climate change could be altering traditional flu patterns, a University of Otago influenza authority says.

Home support providers say funding insufficient

Home support providers have told the Southern District Health Board they cannot provide the service within current funding.

$5m for high-cost medicines

$5m for high-cost medicines

Pharmac has announced plans for a $5 million annual fund for certain high-cost medicines, after pressure from advocates who say drugs for rare diseases stand little chance under current funding rules.